Head-To-Head Analysis: Atossa Genetics (NASDAQ:ATOS) & STERIS (NYSE:STE)

Comparing the medical companies to determine the superior investment

Apr. 13, 2026 at 11:10am

Got story updates? Submit your updates here. ›

An extreme close-up photograph of complex medical machinery and equipment, capturing the precision and power of the devices that enable advancements in healthcare.This cinematic close-up of the inner workings of medical technology symbolizes the critical role that innovation and infrastructure play in the healthcare sector.Seattle Today

Atossa Genetics (NASDAQ:ATOS) and STERIS (NYSE:STE) are both medical companies, but which one is the better investment? This analysis contrasts the two businesses based on factors like risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, and profitability.

Why it matters

This head-to-head analysis provides valuable insights for investors looking to compare two prominent medical companies and determine which one may be the better long-term investment option.

The details

The analysis found that Atossa Genetics has a higher beta of 1.34, indicating its stock is more volatile than the S&P 500, while STERIS has a beta of 1.07. STERIS also has significantly higher institutional ownership at 94.7% compared to Atossa Genetics' 12.7%. Analysts currently have a higher consensus price target for Atossa Genetics, suggesting more potential upside. However, STERIS has higher revenue and earnings than Atossa Genetics.

  • The analysis was published on April 13, 2026.

The players

Atossa Genetics

A clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women's breast cancer and other conditions.

STERIS

A global provider of infection prevention products and services, operating in the healthcare, applied sterilization technologies, life sciences, and dental markets.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the key differences between Atossa Genetics and STERIS, providing investors with valuable information to consider when evaluating which medical company may be the better long-term investment option based on factors like risk, valuation, growth potential, and financial performance.